Thursday, 1 December 2016

Therapeutic Respiratory Devices Market Is Expected To Reach USD 19.2 Billion By 2022: Grand View Research, Inc.



Global therapeutic respiratory devices market is expected to reach USD 19.2 billion by 2022, according to a new report by Grand View Research Inc. Increasing geriatric population contributing towards growing target disease prevalence levels is a key factor expected to attribute towards market growth.
Rising prevalence of disorders such as COPD and sleep apnea is expected to be a critical growth driver. Prevalence of these disorders is expected to constantly rise over the next six years owing to the growing prevalence of cardiovascular disorders, hypertension, obesity, and other lifestyle induced disorders.
Increasing need of emergency treatment for prolonged illnesses and protracted treatment associated with lung diseases in children as well as adults are expected to drive market growth over the next seven years. The introduction of technology innovations is expected to serve as future growth opportunities.


Further key findings from the study suggest:
·         Positive airway pressure devices dominated the product segment in 2014, with market size valued at over 4.0 billion. Growing demand for portable PAP devices and high associated efficacy rates are some key factors expected to drive segment growth.
·         HEPA filtration was the largest technology segment, accounting for over 35.0% of the market share in 2014. High usage of these filters in therapeutic respiratory devices is a major factor contributing towards the segment’s market position.
·         Furthermore, technological advancements in these filters such as the availability of washable HEPA filters and incorporation of HEPA 4 technology is further likely to boost usage rates.
·         Regionally, North America dominated the therapeutic respiratory devices market owing to the presence of high diagnosis rates supported by the presence of sophisticated healthcare infrastructure. Increasing government funding, and the availability of well structured reimbursement framework will also contribute towards healthy market growth.
·         Asia Pacific is expected to witness significant gains, at over 12.0% during the forecast period, driven by the rising incidence of respiratory disorders in the region. Rising healthcare expenditure levels and the presence of high unmet medical need is also a vital growth driver.
·         Key players operating in the therapeutic respiratory devices market include Smiths Medical, GE Healthcare, CareFusion Corporation, Philips Healthcare and Covidien Plc.
·         The market is expected to remain highly competitive, which may see extensive R&D investments aimed at technology innovation, as a widely utilized business strategy.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the global therapeutic respiratory devices market on the basis of products, technology, filters and region:
Product Outlook (Revenue, USD Million, 2012 - 2022)
·         Nebulizers
o    Compressor-based nebulizers
o    Piston-based hand-held nebulizers
o    Ultrasonic nebulizers
·         Humidifiers
o    Heated humidifiers
o    Passover humidifiers
o    Integrated humidifiers
o    Built-in humidifiers
o    Stand-alone humidifiers
·         Oxygen concentrators
o    Fixed oxygen concentrators
o    Portable oxygen concentrators
·         Positive airway pressure devices
o    Continuous positive airway pressure devices
o    Auto-titrating positive airway pressure devices
o    Bi-level positive airway pressure devices
·         Ventilators
o    Adult ventilators
o    Neonatal ventilators
·         Gas Analyzers
o    Capnographs
Technology Outlook (Revenue, USD Million, 2012 - 2022)
·         Electrostatic filtration
·         HEPA filter technology
·         Hollow fiber filtration
·         Microsphere separation
Filters Outlook (Revenue, USD Million, 2012 - 2022)
·         Nebulizer filters
o    Inlet filters
o    Replacement filters
o    Cabinet filters
·         Humidifier filters
o    Wick filters
o    Permanent cleanable filters
o    Mineral absorption pads
o    Demineralization cartridges
·         Positive airway pressure device filters
o    Ultra fine foam inlet filters
o    Polyester non-woven fiber filters
o    Acrylic & polypropylene fiber filters
·         Oxygen concentrators filters
o    HEPA filters
o    Cabinet filters
o    Pre-inlet filters
o    Inlet filters
o    Micro disk filters
o    Felt intake filters
o    Bacterial filters
o    Hollow membrane filters
·         Ventilator filters
o    Mechanical filters
§  HEPA filters
§  ULPA filters
§  Activated carbon filters
o    Electrostatic filters
§  Tribocharged filters
§  Fibrillated filters
Regional Outlook (Revenue, USD Million, 2012 - 2022)
·         North America
o    U.S.
o    Canada
·         Europe
o    Spain
o    Germany
o    France
o    Italy
o    Switzerland
·         Asia Pacific
o    India
o    Japan
o    China
·         Latin America
o    Brazil
o    Mexico
·         Middle East and Africa (MEA)
o    South Africa

Antifungal Drugs Market Was Valued At USD 10.7 Billion In 2015 And Is Expected To Reach A Value Of USD 12.6 Billion By 2025: Grand View Research, Inc.



The global antifungal drugs market was valued at USD 10.7 billion in 2015 and is expected to reach a value of USD 12.6 billion by 2025. The increasing incidence of fungal infections worldwide is the key contributing factor for the growth of the antifungal drugs market in the coming years. Rising adoption of immunosuppressive andantineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics have resulted in the increasing incidence of fungal infections in the recent years.
The growing geriatric population prone to infectious diseases and higher prevalence of chronic conditions, including HIV and cancer, are further contributing toward the rising demand for antifungals to treat opportunistic fungal infections over the forecast period. The large demand for these fungistatic agents is due to the nature of fungal infections, which are difficult to diagnose, yielding high mortality and morbidity rates.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/antifungal-drugs-market

Further Key Findings from the Study Suggest:
·         Echinocandins segment is anticipated to exhibit lucrative growth owing to their cell wall-specific fungicidal property coupled with their broad-spectrum activity against Aspergillus and Candida species without cross-resistance risks
·         Candidiasis indication segment is anticipated to witness the fastest CAGR over the forecast period due to the increasing drug resistance of the Candida speciesto Azoles
·         North America held the largest market share as of 2015, which is attributable to higher awareness levels pertaining to the treatment of fungal infection and presence of target diseases in the population
·         Asia pacific is predicted to exhibit the fastest growth due to improving healthcare facilities coupled with rising government initiatives to create awareness of infectious diseases amongst the population
·         The companies are focusing on the development of effective therapeutic agents for the treatment of systemic fungal infections in immune-compromised patients
·         Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics is predicted to provide this market with lucrative growth opportunities
·         For example, the public-private partnership, namely Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator is anticipated to provide USD 44 million in 2016 and around USD 350 million in the coming 5 years to boost the R&D pipeline
·         The partners involved in this partnership are the U.S. Department of Health and Human Services, the Antimicrobial Resistance Centrein England, and Boston University School of Law

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals  

Grand View Research has segmented the antifungal drugs market by drug class, indication, and region:
Global Antifungal Drugs Class Outlook (Revenue, USD Million, 2014 - 2025)
·         Azoles
·         Echinocandins
·         Polyenes
·         Allylamines
·         Others
Global Antifungal Drugs Indication Outlook (Revenue, USD Million, 2014 - 2025)
·         Dermatophytosis
·         Aspergillosis
·         Candidiasis
·         Others
Antifungal Drugs Regional Outlook (Revenue, USD Million, 2014 - 2025)
·         North America
o    U.S
o    Canada
·         Europe
o    Germany
o    UK
·         Asia Pacific
o    Japan
o    China
o    India
·         Latin America
o    Brazil
o    Mexico
·         The Middle East and Africa
o    South Africa

Doxorubicin Market Was Valued At USD 0.81 Billion In 2015 And Is Expected To Reach A Value Of USD 1.38 Billion By 2024: Grand View Research, Inc.



The global doxorubicin market was valued at USD 0.81 billion in 2015 and is expected to reach a value of USD 1.38 billion by 2024, according to a new report by Grand View Research, Inc. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.
The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: -
·         Leukemia                    60,140
·         Breast cancer             2,46,660
·         Endometrial cancer    60,050
·         Gastric cancer           26,370
·         Liver cancer                39,230
·         Kidney Cancer            62,700
According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.


Further Key Findings from the Study Suggest:
·         In 2015, breast cancer is the largest application of doxorubicin market, having a share of around 21.1%. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.
·         Liver cancer segment is the fastest growing application in this sector. The growing demand for the drug in combination and mono chemotherapies to treat liver cancer over other anticancer drugs is one of the crucial factors that is expected to boost the industry growth.
·         In 2015, North America held majority of market share of over 48.8% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.
·         Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.
·         Some of the key market players are Sun Pharmaceutical Industries Ltd., Pfizer, Inc., Cipla, Inc., Cadila Pharmaceuticals, and SRS Pharmaceuticals Pvt. Ltd.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the Doxorubicin market by application and region:
Doxorubicin Market: Application outlook (Market revenue in USD Million, 2013 - 2024)
·         Ovarian cancer
·         Multiple myeloma
·         Kaposi Sarcoma
·         Leukemia
·         Bone sarcoma
·         Breast cancer
·         Endometrial cancer
·         Gastric cancer
·         Liver cancer
·         Kidney cancer
·         Other cancer
Doxorubicin market regional outlook (Market revenue in USD Million, 2013 - 2024)
·         North America
o    U.S.
o    Canada
·         Europe
o    UK
o    Germany
·         Asia Pacific
o    Japan
o    China
·         Latin America
o    Brazil
o    Mexico
·         Middle East and Africa
o    South Africa